Market Overview:
The India generic injectables market size reached US$ 2.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.9 Billion by 2028, exhibiting a growth rate (CAGR) of 12.4% during 2023-2028.
Generic injectables refer to alternative drugs that are bio-equivalent of their branded counterparts in terms of active ingredients, strength, quality, effectiveness, intended use, and dosage. They are used to treat various life-threatening and chronic diseases, such as cancer, diabetes, rheumatoid arthritis, cardiovascular ailments, and respiratory infections. As compared to innovator drugs, generic injectables offer maximized patient compliance, reduced frequency of drug delivery, limited price erosion, and higher profitability for manufacturers.
The increasing prevalence of chronic diseases in India, due to the rising pollution levels and unhealthy lifestyle of the population are the major factors driving the generic injectables market growth. This, in turn, has led to a rise in the expenditure on innovation in generic injectables for effective drug administration and faster recovery of patients. Additionally, an expansion in the life science industry and rapid technological advancements in drug delivery systems, such as the development of self-injection devices, are contributing to the market growth. Moreover, rising economic development in India has resulted in improved healthcare facilities, which is acting as another growth-inducing factor. Apart from this, the increasing shortage of branded medicines and expiry of patents of branded items, are further creating a positive outlook for the market in the country.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the India generic injectables market report, along with forecasts at the country and regional level from 2023-2028. Our report has categorized the market based on therapeutic area, container and distribution channel.
Breakup by Therapeutic Area:
- Oncology
- Anaesthesia
- Anti-infectives
- Parenteral Nutrition
- Cardiovascular
Breakup by Container:
- Vials
- Ampoules
- Premix
- Prefilled Syringes
Breakup by Distribution Channel:
- Hospitals
- Retail Pharmacy
Breakup by Region:
- North India
- West and Central India
- South India
- East India
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Billion |
Segment Coverage |
Therapeutic Area, Container, Distribution Channel, Region |
Region Covered |
North India, West and Central India, South India, East India |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 2999
Corporate License: US$ 3499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the India generic injectables market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the India generic injectables market?
- What are the key regional markets?
- What is the breakup of the market based on the therapeutic area?
- What is the breakup of the market based on the container?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the India generic injectables market and who are the key players?
- What is the degree of competition in the industry?